<?xml version="1.0" encoding="UTF-8"?>
<collection>
<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd http://dublincore.org/schemas/xmls/qdc/dcterms.xsd"><dc:language>eng</dc:language><dc:creator>Pietsch, Torsten</dc:creator><dc:title>[Neuropathology of medulloblastomas and other CNS embryonal tumors : Precision diagnostics through the integration of genetic markers].</dc:title><dc:subject>info:eu-repo/classification/ddc/610</dc:subject><dc:subject>Cerebellar Neoplasms</dc:subject><dc:subject>Genetic Markers</dc:subject><dc:subject>Humans</dc:subject><dc:subject>Medulloblastoma</dc:subject><dc:subject>Neoplasms, Germ Cell and Embryonal</dc:subject><dc:subject>Neuropathology</dc:subject><dc:subject>Genetic Markers</dc:subject><dc:description>The revised WHO classification of tumors of the central nervous system (CNS) in 2016 introduced the concept of the 'integrated diagnosis.' The definition of medulloblastoma entities now requires a combination of traditional histological information with additional molecular/genetic features. To define the histopathological component of the medulloblastoma diagnosis, tumors have to be assigned to one of the four histological entities: classic, desmoplastic/nodular (DNMB), extensive nodular (MBEN), or large cell/anaplastic (LC/A) medulloblastoma. The genetically defined component is one of the four entities: 'WNT activated', 'SHH activated and TP53 wildtype', 'SHH activated and TP53 mutant', or 'non-WNT/non-SHH medulloblastoma.' Robust and validated methods are available that allow a precise diagnosis of these medulloblastoma entities according to the updated WHO classification and for differential diagnostic purposes. An immunohistochemical analysis of protein markers including ß‑Catenin, Yap1, p75-NGFR, Otx2 and p53, in combination with targeted sequencing and chromosomal copy number assessment (such as FISH analysis for MYC genes), allows a precise stratification of patients for risk-adapted treatment. The group of other embryonic tumors of the central nervous system includes embryonic tumors with multilayered rosettes (ETMR), which frequently carry an amplification of the micro-RNA cluster C19MC and the (ganglio-)neuroblastomas of the CNS. These rare tumors can also be identified by characteristic genetic and immunophenotypic features.</dc:description><dc:source>Der Pathologe 40(2), 140-147 (2019). doi:10.1007/s00292-019-0580-9</dc:source><dc:type>info:eu-repo/semantics/article</dc:type><dc:type>info:eu-repo/semantics/publishedVersion</dc:type><dc:publisher>Springer</dc:publisher><dc:date>2019</dc:date><dc:rights>info:eu-repo/semantics/closedAccess</dc:rights><dc:coverage>DE</dc:coverage><dc:identifier>https://pub.dzne.de/record/140637</dc:identifier><dc:identifier>https://pub.dzne.de/search?p=id:%22DZNE-2020-06959%22</dc:identifier><dc:audience>Researchers</dc:audience><dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1007/s00292-019-0580-9</dc:relation><dc:relation>info:eu-repo/semantics/altIdentifier/issn/1432-1963</dc:relation><dc:relation>info:eu-repo/semantics/altIdentifier/pmid/pmid:30790012</dc:relation><dc:relation>info:eu-repo/semantics/altIdentifier/issn/0172-8113</dc:relation></oai_dc:dc>

</collection>